NuCana shows clinical activity for NUC-7738 in melanoma patients Dec 10, 2025 08:03AM
NuCana secures patent for cancer drug NUC-7738 in China Nov 5, 2025 08:03AM
NuCana reports clinical data for NUC-3373 cancer treatment combination Oct 14, 2025 08:06AM
NuCana regains compliance with NASDAQ listing requirements Sep 5, 2025 08:01AM
NuCana implements 1-for-200 reverse ADS split effective August 11 Aug 1, 2025 04:06PM


Jul 21, 2025 08:05AM NuCana cancels remaining Series A warrants for $3.6 million payment
Jul 11, 2025 10:31AM NuCana plans reverse stock split to meet Nasdaq requirements
May 6, 2025 08:30AM NuCana (NCNA) Prices $7M Offering
Nov 11, 2024 07:01AM NuCana (NCNA) Reports Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373
Sep 25, 2024 04:02PM NuCana (NCNA) Announces Grant of US Composition-of-Matter Patent for NUC-7738
Sep 3, 2024 05:34AM NuCana (NCNA) PT Lowered to $25 at Oppenheimer
Aug 30, 2024 07:16AM William Blair Downgrades NuCana (NCNA) to Market Perform
Aug 29, 2024 04:02PM NuCana (NCNA) Says NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee
Aug 29, 2024 04:01PM NuCana (NCNA) Halted, News Pending
Jul 22, 2024 06:55AM NuCana (NCNA) PT Raised to $150 at Oppenheimer, 'the stage is set for '3373 to at least show better safety/tolerability'